E. David Crawford, MD, and Daniel P. Petrylak, MD, discuss PARP inhibition, TALAPRO-3, HRR alterations, and genomic testing in metastatic prostate cancer.
Read More
Prospective OPTYX registry findings support relugolix adherence, safety, and quality of life.
Read More
Dr. Scott B. Sellinger reviews PTEN deficiency, AKT signaling, and CAPItello-281 findings in metastatic hormone-sensitive prostate cancer.
Read More
Helen L. Bernie, DO, MPH, reviews evidence on testosterone therapy and prostate cancer risk and management.
Read More
A practical review of strengths, limits, and “gray areas” in the AUA erectile dysfunction guideline.
Read More